DNA Vaccines: Ready for Prime Time?

Overview

Journal Nat Rev Genet

Specialty Genetics

Date 2008 Sep 11

PMID 18781156

Citations 430

Authors

Michele A Kutzler

David B Weiner

Affiliations

Soon will be listed here.

Abstract

Since the discovery, over a decade and a half ago, that genetically engineered DNA can be delivered in vaccine form and elicit an immune response, there has been much progress in understanding the basic biology of this platform. A large amount of data has been generated in preclinical model systems, and more sustained cellular responses and more consistent antibody responses are being observed in the clinic. Four DNA vaccine products have recently been approved, all in the area of veterinary medicine. These results suggest a productive future for this technology as more optimized constructs, better trial designs and improved platforms are being brought into the clinic.

Citing Articles

Beyond the Needle: Innovative Microneedle-Based Transdermal Vaccination.

Nguyen H Medicines (Basel). 2025; 12(1).

PMID: 39982324 PMC: 11843882. DOI: 10.3390/medicines12010004.

Cancer vaccines: current status and future directions.

Zhou Y, Wei Y, Tian X, Wei X J Hematol Oncol. 2025; 18(1):18.

PMID: 39962549 PMC: 11834487. DOI: 10.1186/s13045-025-01670-w.

Structural engineering of stabilized, expanded epitope nanoparticle vaccines for HPV.

Helble M, Zhu X, Bhojnagarwala P, Liaw K, Gao Y, Kim A Front Immunol. 2025; 16:1535261.

PMID: 39958352 PMC: 11826081. DOI: 10.3389/fimmu.2025.1535261.

Development of nucleic acid-based vaccines against dengue and other mosquito-borne flaviviruses: the past, present, and future.

Bello M, Alsaadi A, Naeem A, Almahboub S, Bosaeed M, Aljedani S Front Immunol. 2025; 15():1475886.

PMID: 39840044 PMC: 11747009. DOI: 10.3389/fimmu.2024.1475886.

Pulmonary Delivery of Nonviral Nucleic Acid-Based Vaccines With Spotlight on Gold Nanoparticles.

Araujo Cirne C, Foldvari M Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2025; 17(1):e70000.

PMID: 39800783 PMC: 11725562. DOI: 10.1002/wnan.70000.

References

Thacker E, Holtkamp D, Khan A, Brown P, Draghia-Akli R . Plasmid-mediated growth hormone-releasing hormone efficacy in reducing disease associated with Mycoplasma hyopneumoniae and porcine reproductive and respiratory syndrome virus infection. J Anim Sci. 2006; 84(3):733-42. DOI: 10.2527/2006.843733x. View

Ito H, Sommer M, Zerboni L, He H, Boucaud D, Hay J . Promoter sequences of varicella-zoster virus glycoprotein I targeted by cellular transactivating factors Sp1 and USF determine virulence in skin and T cells in SCIDhu mice in vivo. J Virol. 2002; 77(1):489-98. PMC: 140613. DOI: 10.1128/jvi.77.1.489-498.2003. View

Wang R, Doolan D, Le T, Hedstrom R, Coonan K, Charoenvit Y . Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science. 1998; 282(5388):476-80. DOI: 10.1126/science.282.5388.476. View

Tang D, DeVit M, Johnston S . Genetic immunization is a simple method for eliciting an immune response. Nature. 1992; 356(6365):152-4. DOI: 10.1038/356152a0. View

Catanzaro A, Koup R, Roederer M, Bailer R, Enama M, Moodie Z . Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis. 2006; 194(12):1638-49. PMC: 2428071. DOI: 10.1086/509258. View

Kwissa M, von Kampen V, Zurbriggen R, GLUCK R, Reimann J, Schirmbeck R . Efficient vaccination by intradermal or intramuscular inoculation of plasmid DNA expressing hepatitis B surface antigen under desmin promoter/enhancer control. Vaccine. 2000; 18(22):2337-44. DOI: 10.1016/s0264-410x(00)00030-x. View

Kothe D, Decker J, Li Y, Weng Z, Bibollet-Ruche F, Zammit K . Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology. 2006; 360(1):218-34. PMC: 1945152. DOI: 10.1016/j.virol.2006.10.017. View

Buchan S, Gronevik E, Mathiesen I, King C, Stevenson F, Rice J . Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen. J Immunol. 2005; 174(10):6292-8. DOI: 10.4049/jimmunol.174.10.6292. View

Ruprecht R . Live attenuated AIDS viruses as vaccines: promise or peril?. Immunol Rev. 1999; 170:135-49. DOI: 10.1111/j.1600-065x.1999.tb01335.x. View

10.

Nichols W, Ledwith B, Manam S, Troilo P . Potential DNA vaccine integration into host cell genome. Ann N Y Acad Sci. 1995; 772:30-9. DOI: 10.1111/j.1749-6632.1995.tb44729.x. View

11.

Imoto J, Konishi E . Needle-free jet injection of a mixture of Japanese encephalitis DNA and protein vaccines: a strategy to effectively enhance immunogenicity of the DNA vaccine in a murine model. Viral Immunol. 2005; 18(1):205-12. DOI: 10.1089/vim.2005.18.205. View

12.

Kohler G, Milstein C . Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975; 256(5517):495-7. DOI: 10.1038/256495a0. View

13.

Miller M, Rekas G, Dayball K, Wan Y, Bramson J . The efficacy of electroporated plasmid vaccines correlates with long-term antigen production in vivo. Vaccine. 2004; 22(20):2517-23. DOI: 10.1016/j.vaccine.2004.01.019. View

14.

Minor P . Regulatory issues in the use of DNA vaccines. Ann N Y Acad Sci. 1995; 772:170-7. DOI: 10.1111/j.1749-6632.1995.tb44742.x. View

15.

Shiver J, Fu T, Chen L, Casimiro D, Davies M, Evans R . Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002; 415(6869):331-5. DOI: 10.1038/415331a. View

16.

Cui Z, Baizer L, Mumper R . Intradermal immunization with novel plasmid DNA-coated nanoparticles via a needle-free injection device. J Biotechnol. 2003; 102(2):105-15. DOI: 10.1016/s0168-1656(03)00029-4. View

17.

Heller L, Pottinger C, Jaroszeski M, Gilbert R, Heller R . In vivo electroporation of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanomas combined with electrochemotherapy induces long-term antitumour immunity. Melanoma Res. 2001; 10(6):577-83. DOI: 10.1097/00008390-200012000-00010. View

18.

Tezel A, Paliwal S, Shen Z, Mitragotri S . Low-frequency ultrasound as a transcutaneous immunization adjuvant. Vaccine. 2005; 23(29):3800-7. DOI: 10.1016/j.vaccine.2005.02.027. View

19.

Ellenberger D, Li B, Lupo L, Owen S, Nkengasong J, Smith J . Generation of a consensus sequence from prevalent and incident HIV-1 infections in West Africa to guide AIDS vaccine development. Virology. 2002; 302(1):155-63. DOI: 10.1006/viro.2002.1577. View

20.

Anderson D, Peng W, Akinc A, Hossain N, Kohn A, Padera R . A polymer library approach to suicide gene therapy for cancer. Proc Natl Acad Sci U S A. 2004; 101(45):16028-33. PMC: 528737. DOI: 10.1073/pnas.0407218101. View